2032: hVIVO Interview - CEO Mo Khan on New RSV Human Challenge Trial & Company Growth

from The Vox Markets Podcast · host Vox Markets Podcast

In this exclusive interview, hVIVO CEO Mo Khan discusses the company’s latest human challenge trial contract with Inhalon Biopharma, testing a next-generation mucosal RSV antiviral. Mo addresses industry speculation around RSV trials, explains why RSV antivirals remain a key growth area, and shares insights on hVIVO’s strong sales pipeline conversion, with this being their fourth new study announcement in under two months. He also provides a quick update on the recent CRS acquisition and what’s next for the company.

NOW PLAYING

0:00 8:42

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of The Vox Markets Podcast?

This episode is 8 minutes long.

When was this The Vox Markets Podcast episode published?

This episode was published on February 3, 2025.

What is this episode about?

Can I download this The Vox Markets Podcast episode?

Yes, you can download this episode by clicking the download button on the episode player, or subscribe to the podcast in your preferred podcast app for automatic downloads.

URL copied to clipboard!